Volume5, Issue0 (2022) | undefined

Cancer Drug Resistance

Search Log In

Editor-in-Chief: Godefridus J. Peters

Indexing: ESCI, PMC, Scopus, CAS, CNKI, Dimensions, Lens, Embase,

Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)] Submission to first decision: 10 days

Hot Keywords

ResistanceDrug deliveryNanomedicineTumor microenvironmentImmune checkpoint inhibitorsTarget therapyImmunotherapyRadiotherapyFerroptosisPARP inhibitorsMYCABC transportersAutophagyMetabolismMechanismsPrecision medicineExtracellular vesiclesStem cellBiomarkerOvarian cancerRenal cell carcinomaProstate cancerBreast cancerColorectal cancerMyeloid leukemiaNon-small cell lung cancerPancreatic cancerHead and neck cancerSquamous cell carcinomaMitochondria

Home

About

Publish with us

Articles

Special Issues

Special Collections

Volumes

Pre-onlines

Features

Home Articles Special Issues Volumes Webinars Videos

Cancer Drug Resistance

Editor-in-Chief: Godefridus J. Peters

Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]

Submission to first decision: 10 days

Home Articles Special Issues Volumes Webinars Videos

Home Volumes

Volume

Table of Contents (74 articles)

Auranofin and its analogs as prospective agents for the treatment of colorectal cancer

Lara Massai, ... Luigi Messori

Pages 1-14

Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study

Xiaojin Guo, ... Fengying Wu

Pages 15-24

Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance

Jeff Rytlewski, ... Varun Monga

Pages 25-35

Emerging actionable targets to treat therapy-resistant colorectal cancers

Emanuela Grassilli, Maria Grazia Cerrito

Maria Grazia Cerrito

Pages 36-63

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer

Bernhard Biersack

Bernhard Biersack

, ... Michael Höpfner

Pages 64-79

Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma

Samson Ghilu, ... Peter J. Houghton

Pages 80-89

Understanding sarcoma drug resistance one cell at a time

Salah-Eddine Cherradi-Lamhamedi

Salah-Eddine Cherradi-Lamhamedi

, ... Joseph A. Ludwig

Pages 90-92

Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance

Md Imtiaz Khalil, Arrigo De Benedetti

Arrigo De Benedetti

Pages 93-101

Tumor-derived exosomes: immune properties and clinical application in lung cancer

Jing Wu, ... Pengfei Zhang

Pages 102-113

Immunotherapy resistance of lung cancer

Xin Yu, ... Chunxia Su

Chunxia Su

Pages 114-128

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer

Yunchang Li, ... Chuan Xu

Pages 129-146

Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer

Peng Ding, ... Xiaorong Dong

Pages 147-164

ONECUT2 as a key mediator of androgen receptor-independent cell growth and neuroendocrine differentiation in castration-resistant prostate cancer

WonSeok William Choi, ... Jianqing Lin

Jianqing Lin

Pages 165-170

Drug resistance and minimal residual disease in multiple myeloma

Alessandro Gozzetti

Alessandro Gozzetti

, ... Monica Bocchia

Pages 171-183

Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma

Camille Jubelin, ... Dominique Heymann

Dominique Heymann

Pages 184-198

Emerging mechanisms of immunotherapy resistance in sarcomas

Vaia Florou, Breelyn A. Wilky

Pages 199-213

Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma

Claire Comerford, ... John Quinn

Pages 214-228

Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy

Casey D. Stefanski, Jenifer R. Prosperi

Pages 229-232

Lysosome-mediated chemoresistance in acute myeloid leukemia

Laia Cuesta-Casanovas, ... Ruth M. Risueño

Pages 233-244

In vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivity

Gianluigi De Renzi, ... Chiara Nicolazzo

Pages 245-260

Circular RNA drives resistance to anti-PD-1 immunotherapy by regulating the miR-30a-5p/SOX4 axis in non-small cell lung cancer

Jing Wu, ... Peng-Fei Zhang

Pages 261-270

Cancer drug resistance in multiple myeloma

Fatih M. Uckun

Fatih M. Uckun

Pages 271-276

The complex relationship between multiple drug resistance and the tumor pH gradient: a review

Tomas Koltai

Tomas Koltai

Pages 277-303

Mechanisms of chemotherapy resistance in ovarian cancer

Mylena Ortiz, ... Sachi Horibata

Sachi Horibata

Pages 304-316

Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approach

Naushair Hussain, ... Kartick C. Pramanik

Pages 317-327

Immune checkpoint inhibitor resistance in soft tissue sarcoma

Vanessa Eulo, Brian A. Van Tine

Pages 328-338

Natural bioactive compounds: a potential therapeutic strategy to sensitize bladder cancer to cisplatin treatment?

Vicenç Ruiz de Porras

Pages 339-343

Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication

Quinty Hansen, ... Jacqueline Cloos

Jacqueline Cloos

Pages 344-367

DNA damage and metabolic mechanisms of cancer drug resistance

Deanna Tiek, Shi-Yuan Cheng

Shi-Yuan Cheng

Pages 368-379

Venetoclax resistance: mechanistic insights and future strategies

Faustine Ong, ... Marina Y. Konopleva

Pages 380-400

RIP140 regulates POLK gene expression and the response to alkylating drugs in colon cancer cells

Pascale Palassin, ... Audrey Castet-Nicolas

Pages 401-414

Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective

Peter G. Rose

Pages 415-423

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer

Michael J. Flynn, Jonathan A. Ledermann

Jonathan A. Ledermann

Pages 424-435

Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response

Tengda Zhao, ... Ke Yang

Pages 436-450

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”

Tanja Pejovic, ... Gordon Mills

Pages 451-458

Role of prostate cancer stem-like cells in the development of antiandrogen resistance

Prem Prakash Kushwaha, ... Sanjay Gupta

Sanjay Gupta

Pages 459-471

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer

Ahmed M. Elshazly, David A. Gewirtz

Pages 472-486

Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours

Ravi Velaga, ... Masakazu Toi

Pages 487-497

Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance

Gregory Bick, ... Xiaoting Zhang

Pages 498-510

Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival

Yuting Lu, Yongzhao Shao

Pages 511-533

Emerging insights to lung cancer drug resistance

Chunxia Su

Chunxia Su

Pages 534-540

Liquid biopsies in primary and secondary bone cancers

Argia Ucci

Argia Ucci

, ... Marco Ponzetti

Pages 541-559

Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer

Alex J. Eustace, ... Paul J. Buchanan

Pages 560-576

Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistance

Kenneth K. W. To

Kenneth K. W. To

, William C. S. Cho

William C. S. Cho

Pages 577-594

Electrochemotherapy using thin-needle electrode improves recovery in feline nasal planum squamous cell carcinoma - a translational model

Matías Tellado, ... Felipe Maglietti

Felipe Maglietti

Pages 595-611

Role of extracellular vesicles secretion in paclitaxel resistance of prostate cancer cells

Ashish Kumar

Ashish Kumar

, ... Gagan Deep

Gagan Deep

Pages 612-624

AdipoRon and Pancreatic Ductal Adenocarcinoma: a future perspective in overcoming chemotherapy-induced resistance?

Luigi Sapio, ... Silvio Naviglio

Silvio Naviglio

Pages 625-636

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy

Rebekah Summey

Rebekah Summey

, Denise Uyar

Pages 637-646

Therapeutics to harness the immune microenvironment in multiple myeloma

James J. Ignatz-Hoover, James J. Driscoll

Pages 647-661

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report

Siew-Fei Ngu, ... Karen K. L. Chan

Pages 662-666

Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo

Amani Yehya, ... Wassim Abou-Kheir

Pages 667-690

Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer

Amy H. Tang, ... Harry D. Bear

Pages 691-702

Base excision repair accessory factors in senescence avoidance and resistance to treatments

Elise Vickridge, ... Alain Nepveu

Pages 703-720

GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies

Khoa Nguyen, ... Matthew E. Burow

Pages 721-726

Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer

Sasha C. Main, ... Scott V. Bratman

Pages 727-748

Microvesicles: the functional mediators in sorafenib resistance

Cong He, ... Zhong-Dang Xiao

Pages 749-761

An overview of resistance to chemotherapy in osteosarcoma and future perspectives

Dorian Yarih Garcia-Ortega

Dorian Yarih Garcia-Ortega

, ... Marlid Cruz-Ramos

Marlid Cruz-Ramos

Pages 762-793

Insight into the molecular mechanisms of gastric cancer stem cell in drug resistance of gastric cancer

Jixian Xiong

Jixian Xiong

, ... Li Fu

Li Fu

Pages 794-813

Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells

Mario Cioce

Mario Cioce

, ... Vito Michele Fazio

Pages 814-828

A nano-enhanced vaccine for metastatic melanoma immunotherapy

Katelyn E. Salotto, ... Helena W. Snyder

Pages 829-845

New insights for drug resistance in metastatic castration-resistant prostate cancer

Prem Prakash Kushwaha, Sanjay Gupta

Sanjay Gupta

Pages 846-849

Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces

Ahmad R. Safa

Pages 850-872

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer

Lisa D. Eli

Lisa D. Eli

, Shyam M. Kavuri

Shyam M. Kavuri

Pages 873-881

Improving HER2 testing reproducibility in HER2-low breast cancer

Elham Sajjadi, ... Nicola Fusco

Nicola Fusco

Pages 882-888

Cancer-associated fibroblasts as accomplices to confer therapeutic resistance in cancer

Wenyu Wang, ... Qiang Yu

Pages 889-901

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance

Fatih M. Uckun

Fatih M. Uckun

, Sanjive Qazi

Pages 902-916

Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach

Leroy Lowe, ... Dean W. Felsher

Dean W. Felsher

Pages 917-925

Discovery of the inhibitor of DNA binding 1 as a novel marker for radioresistance in pancreatic cancer using genome-wide RNA-seq

Oscar Zuniga, ... Adam R. Wolfe

Pages 926-938

Aberrant Notch signaling in gliomas: a potential landscape of actionable converging targets for combination approach in therapies resistance

Maria D’Amico, Francesca De Amicis

Francesca De Amicis

Pages 939-953

Perspectives of metal-organic framework nanosystem to overcome tumor drug resistance

Huafeng Wang, ... Tianxiang Wei

Tianxiang Wei

Pages 954-970

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls

Stefania Morganti

Stefania Morganti

, ... Carmen Criscitiello

Carmen Criscitiello

Pages 971-980

Cancer resistance to immunotherapy: What is the role of cancer stem cells?

Gourab Gupta, ... Hexin Chen

Pages 981-994

Association between genome-wide epigenetic and genetic alterations in breast cancer tissue and response to HER2-targeted therapies in HER2-positive breast cancer patients: new findings and a systematic review

Daniela Furrer, ... Caroline Diorio

Pages 995-1015

The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them

Danilo Rocco, ... Cesare Gridelli

Pages 1016-1024

Actions for 0 selected articles

Cancer Drug Resistance

ISSN 2578-532X (Online)

editorial@cdrjournal.com

Navigation

Follow Us

LinkedIn
Twitter
WeChat

Navigation

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

partners@oaepublish.com

Discover Content

Language Editing

Layout & Production

Graphical Abstracts

Video Abstracts

Conference Organizer

Strategic Collaborators

Follow OAE

© 2016-2025 OAE Publishing Inc., except certain content provided by third parties

Privacy Cookies Terms of Service